WGS · Nasdaq · CIK 0001818331

GeneDx Holdings Corp.

GeneDx Holdings Corp.’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 18, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $427.5M and net income of -$21.0M, according to its XBRL data on EDGAR. Its EDGAR record lists 51 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$427.5M
Net income, FY2025
-$21.0M
Form 4 filings on record, past 12 months
51

Company overview

Legal name (as filed)
GeneDx Holdings Corp.
Ticker
WGS
SEC Central Index Key (CIK)
0001818331
Industry (SIC)
Services-Health Services (code 8000)
Business address
STAMFORD, CT
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1998 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from GeneDx Holdings Corp.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$212.2MFY2021$234.7MFY2022$202.6MFY2023$305.4MFY2024$427.5MFY2025
Net income
-$245.4MFY2021-$549.0MFY2022-$175.8MFY2023-$52.3MFY2024-$21.0MFY2025
WGS annual results
ItemFY2021
ended Dec 31, 2021
FY2022
ended Dec 31, 2022
FY2023
ended Dec 31, 2023
FY2024
ended Dec 31, 2024
FY2025
ended Dec 31, 2025
Revenue$212.2M$234.7M$202.6M$305.4M$427.5M
Net income-$245.4M-$549.0M-$175.8M-$52.3M-$21.0M
Diluted EPS-$2.27-$53.63-$7.23-$1.94-$0.73
Total assets$554.1M$490.9M$418.8M$419.4M$523.7M
Cash and equivalents$400.6M$123.9M$99.7M$85.2M$105.0M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

WGS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 23, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 3, 20268-KResults of operations· period Aug 3, 2026Document · Index
Apr 30, 2026DEF 14ADefinitive proxy statement· period Dec 31, 2025Document · Index

Recent SEC filings

The 40 newest documents filed by or about GeneDx Holdings Corp., by form type:

4 ×248-K ×4SCHEDULE 13D/A ×3144 ×2SCHEDULE 13G ×210-Q ×23 ×1SCHEDULE 13G/A ×125-NSE ×1
WGS recent filings
FiledFormWhat it isOriginal
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 17, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 9, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 9, 2026Document · Index
Sep 3, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 1, 2026Document · Index
Sep 1, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 1, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 11, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 7, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 3, 20268-KResults of operations· period Aug 3, 2026Document · Index
Jul 28, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 21, 202625-NSE25-NSEDocument · Index
Jul 1, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 29, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20268-KShareholder vote results· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jun 16, 20263Initial statement of beneficial ownership· period Jun 15, 2026Document · Index
Jun 16, 20268-KDirector or officer change; Regulation FD disclosure· period Jun 15, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 8, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 4, 2026Document · Index
Jun 3, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026Document · Index
May 22, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
May 20, 20264Statement of changes in beneficial ownership (insider trade)· period May 18, 2026Document · Index
May 15, 20264Statement of changes in beneficial ownership (insider trade)· period May 13, 2026Document · Index
May 15, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
May 11, 20264Statement of changes in beneficial ownership (insider trade)· period May 7, 2026Document · Index
May 11, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
May 11, 20264Statement of changes in beneficial ownership (insider trade)· period May 7, 2026Document · Index
May 4, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 4, 20268-KResults of operations· period May 4, 2026Document · Index

Insider filing activity

51 Form 4 filings appear in GeneDx Holdings Corp.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Services-Health Services

All 8 companies in Services-Health Services· Companies headquartered in Connecticut

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001818331 and XBRL company facts. GeneDx Holdings Corp. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.